Enhanced cardiovascular function and energy level by a novel chromium (III)-supplement

Mahesh Thirunavukkarasu, SureshVarma Penumathsa, B. Juhász, Lijun Zhan, Manashi Bagchi, Taharat Yasmin, Michael A. Shara, Hemant S. Thatte, Debasis Bagchi, Nilanjana Maulik

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

The impetus for the novel Energy Formula (EF) which combines the niacin-bound chromium (III) (0.45%) (NBC), standardized extract of Withania somnifera extracts (10.71%), caffeine (22.76%), D-ribose (10.71%) and selected amino acids such as phenylalanine, taurine and glutamine (55.37%) was based on the knowledge of the cardioprotective potentials of the Withania somnifera extract, caffeine and D-ribose as well as their abilities to increase energy levels and the abilities of amino acids to increase the muscle mass and energy levels. The effect of oral supplementation of EF on the safety, myocardial energy levels and cardioprotective ability were investigated in an ischemic-reperfused myocardium model in both male and female Sprague-Dawley rats over 90 days trial period. At the completion of 90 days, the EF-treated male and female rats gained 9.4% and 3.1% less body weights, respectively, as compared to their corresponding control groups. No significant difference was found in the levels of lipid peroxidation and activities of hepatic Aspartate transaminase, Alanine transaminase and Alkaline phosphatase in EF treatment when compared with control animals. The male and female rat hearts were subjected to 30 min of global ischemia followed by 2 h of reperfusion at 30 and 90 days of EF treatment. Cardiovascular functions including heart rate, coronary flow, aortic flow, dp/dtmax, left ventricular developed pressure (LVDP) and infarct size were monitored. The levels of myocardial adenosine triphosphate (ATP), creatine phosphate (CP), phospho-adenosine monophosphate kinase (p-AMPK) levels, were analyzed at the end of 30 and 90 days of treatment. Significant improvement was observed in all parameters in the EF treatment groups as compared to their corresponding controls. Thus the niacin-bound chromium (III) based energy formula is safe and effective supplement to boost energy levels and cardioprotection.

Original languageEnglish
Pages (from-to)53-67
Number of pages15
JournalBioFactors
Volume27
Issue number1-4
Publication statusPublished - 2006

Fingerprint

Chromium
Withania
Electron energy levels
Ribose
Niacin
Caffeine
Rats
Adenosine Kinase
Amino Acids
Phosphocreatine
Taurine
Ventricular Pressure
Adenosine Monophosphate
Aspartate Aminotransferases
Glutamine
Alanine Transaminase
Phenylalanine
Lipid Peroxidation
Reperfusion
Alkaline Phosphatase

Keywords

  • ATP
  • Cardiac functions
  • Chromium (III)
  • CP
  • D-ribose
  • Glutamine
  • Ischemia-reperfusion injury
  • p-AMPK
  • Phenylalanine
  • Taurine

ASJC Scopus subject areas

  • Biochemistry

Cite this

Thirunavukkarasu, M., Penumathsa, S., Juhász, B., Zhan, L., Bagchi, M., Yasmin, T., ... Maulik, N. (2006). Enhanced cardiovascular function and energy level by a novel chromium (III)-supplement. BioFactors, 27(1-4), 53-67.

Enhanced cardiovascular function and energy level by a novel chromium (III)-supplement. / Thirunavukkarasu, Mahesh; Penumathsa, SureshVarma; Juhász, B.; Zhan, Lijun; Bagchi, Manashi; Yasmin, Taharat; Shara, Michael A.; Thatte, Hemant S.; Bagchi, Debasis; Maulik, Nilanjana.

In: BioFactors, Vol. 27, No. 1-4, 2006, p. 53-67.

Research output: Contribution to journalArticle

Thirunavukkarasu, M, Penumathsa, S, Juhász, B, Zhan, L, Bagchi, M, Yasmin, T, Shara, MA, Thatte, HS, Bagchi, D & Maulik, N 2006, 'Enhanced cardiovascular function and energy level by a novel chromium (III)-supplement', BioFactors, vol. 27, no. 1-4, pp. 53-67.
Thirunavukkarasu M, Penumathsa S, Juhász B, Zhan L, Bagchi M, Yasmin T et al. Enhanced cardiovascular function and energy level by a novel chromium (III)-supplement. BioFactors. 2006;27(1-4):53-67.
Thirunavukkarasu, Mahesh ; Penumathsa, SureshVarma ; Juhász, B. ; Zhan, Lijun ; Bagchi, Manashi ; Yasmin, Taharat ; Shara, Michael A. ; Thatte, Hemant S. ; Bagchi, Debasis ; Maulik, Nilanjana. / Enhanced cardiovascular function and energy level by a novel chromium (III)-supplement. In: BioFactors. 2006 ; Vol. 27, No. 1-4. pp. 53-67.
@article{759f14aae6ec487090fcf9049247327c,
title = "Enhanced cardiovascular function and energy level by a novel chromium (III)-supplement",
abstract = "The impetus for the novel Energy Formula (EF) which combines the niacin-bound chromium (III) (0.45{\%}) (NBC), standardized extract of Withania somnifera extracts (10.71{\%}), caffeine (22.76{\%}), D-ribose (10.71{\%}) and selected amino acids such as phenylalanine, taurine and glutamine (55.37{\%}) was based on the knowledge of the cardioprotective potentials of the Withania somnifera extract, caffeine and D-ribose as well as their abilities to increase energy levels and the abilities of amino acids to increase the muscle mass and energy levels. The effect of oral supplementation of EF on the safety, myocardial energy levels and cardioprotective ability were investigated in an ischemic-reperfused myocardium model in both male and female Sprague-Dawley rats over 90 days trial period. At the completion of 90 days, the EF-treated male and female rats gained 9.4{\%} and 3.1{\%} less body weights, respectively, as compared to their corresponding control groups. No significant difference was found in the levels of lipid peroxidation and activities of hepatic Aspartate transaminase, Alanine transaminase and Alkaline phosphatase in EF treatment when compared with control animals. The male and female rat hearts were subjected to 30 min of global ischemia followed by 2 h of reperfusion at 30 and 90 days of EF treatment. Cardiovascular functions including heart rate, coronary flow, aortic flow, dp/dtmax, left ventricular developed pressure (LVDP) and infarct size were monitored. The levels of myocardial adenosine triphosphate (ATP), creatine phosphate (CP), phospho-adenosine monophosphate kinase (p-AMPK) levels, were analyzed at the end of 30 and 90 days of treatment. Significant improvement was observed in all parameters in the EF treatment groups as compared to their corresponding controls. Thus the niacin-bound chromium (III) based energy formula is safe and effective supplement to boost energy levels and cardioprotection.",
keywords = "ATP, Cardiac functions, Chromium (III), CP, D-ribose, Glutamine, Ischemia-reperfusion injury, p-AMPK, Phenylalanine, Taurine",
author = "Mahesh Thirunavukkarasu and SureshVarma Penumathsa and B. Juh{\'a}sz and Lijun Zhan and Manashi Bagchi and Taharat Yasmin and Shara, {Michael A.} and Thatte, {Hemant S.} and Debasis Bagchi and Nilanjana Maulik",
year = "2006",
language = "English",
volume = "27",
pages = "53--67",
journal = "BioFactors",
issn = "0951-6433",
publisher = "Wiley-Blackwell",
number = "1-4",

}

TY - JOUR

T1 - Enhanced cardiovascular function and energy level by a novel chromium (III)-supplement

AU - Thirunavukkarasu, Mahesh

AU - Penumathsa, SureshVarma

AU - Juhász, B.

AU - Zhan, Lijun

AU - Bagchi, Manashi

AU - Yasmin, Taharat

AU - Shara, Michael A.

AU - Thatte, Hemant S.

AU - Bagchi, Debasis

AU - Maulik, Nilanjana

PY - 2006

Y1 - 2006

N2 - The impetus for the novel Energy Formula (EF) which combines the niacin-bound chromium (III) (0.45%) (NBC), standardized extract of Withania somnifera extracts (10.71%), caffeine (22.76%), D-ribose (10.71%) and selected amino acids such as phenylalanine, taurine and glutamine (55.37%) was based on the knowledge of the cardioprotective potentials of the Withania somnifera extract, caffeine and D-ribose as well as their abilities to increase energy levels and the abilities of amino acids to increase the muscle mass and energy levels. The effect of oral supplementation of EF on the safety, myocardial energy levels and cardioprotective ability were investigated in an ischemic-reperfused myocardium model in both male and female Sprague-Dawley rats over 90 days trial period. At the completion of 90 days, the EF-treated male and female rats gained 9.4% and 3.1% less body weights, respectively, as compared to their corresponding control groups. No significant difference was found in the levels of lipid peroxidation and activities of hepatic Aspartate transaminase, Alanine transaminase and Alkaline phosphatase in EF treatment when compared with control animals. The male and female rat hearts were subjected to 30 min of global ischemia followed by 2 h of reperfusion at 30 and 90 days of EF treatment. Cardiovascular functions including heart rate, coronary flow, aortic flow, dp/dtmax, left ventricular developed pressure (LVDP) and infarct size were monitored. The levels of myocardial adenosine triphosphate (ATP), creatine phosphate (CP), phospho-adenosine monophosphate kinase (p-AMPK) levels, were analyzed at the end of 30 and 90 days of treatment. Significant improvement was observed in all parameters in the EF treatment groups as compared to their corresponding controls. Thus the niacin-bound chromium (III) based energy formula is safe and effective supplement to boost energy levels and cardioprotection.

AB - The impetus for the novel Energy Formula (EF) which combines the niacin-bound chromium (III) (0.45%) (NBC), standardized extract of Withania somnifera extracts (10.71%), caffeine (22.76%), D-ribose (10.71%) and selected amino acids such as phenylalanine, taurine and glutamine (55.37%) was based on the knowledge of the cardioprotective potentials of the Withania somnifera extract, caffeine and D-ribose as well as their abilities to increase energy levels and the abilities of amino acids to increase the muscle mass and energy levels. The effect of oral supplementation of EF on the safety, myocardial energy levels and cardioprotective ability were investigated in an ischemic-reperfused myocardium model in both male and female Sprague-Dawley rats over 90 days trial period. At the completion of 90 days, the EF-treated male and female rats gained 9.4% and 3.1% less body weights, respectively, as compared to their corresponding control groups. No significant difference was found in the levels of lipid peroxidation and activities of hepatic Aspartate transaminase, Alanine transaminase and Alkaline phosphatase in EF treatment when compared with control animals. The male and female rat hearts were subjected to 30 min of global ischemia followed by 2 h of reperfusion at 30 and 90 days of EF treatment. Cardiovascular functions including heart rate, coronary flow, aortic flow, dp/dtmax, left ventricular developed pressure (LVDP) and infarct size were monitored. The levels of myocardial adenosine triphosphate (ATP), creatine phosphate (CP), phospho-adenosine monophosphate kinase (p-AMPK) levels, were analyzed at the end of 30 and 90 days of treatment. Significant improvement was observed in all parameters in the EF treatment groups as compared to their corresponding controls. Thus the niacin-bound chromium (III) based energy formula is safe and effective supplement to boost energy levels and cardioprotection.

KW - ATP

KW - Cardiac functions

KW - Chromium (III)

KW - CP

KW - D-ribose

KW - Glutamine

KW - Ischemia-reperfusion injury

KW - p-AMPK

KW - Phenylalanine

KW - Taurine

UR - http://www.scopus.com/inward/record.url?scp=33748931824&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748931824&partnerID=8YFLogxK

M3 - Article

C2 - 17012764

AN - SCOPUS:33748931824

VL - 27

SP - 53

EP - 67

JO - BioFactors

JF - BioFactors

SN - 0951-6433

IS - 1-4

ER -